Abstract
Myasthenia gravis is a disorder of neuromuscular transmission that results in skeletal muscle weakness. The affected individual produces antibodies that are directed against their own nicotinic acetylcholine receptors. The circulating antibodies interfere with binding of acetylcholine to the ....
| Original language | English |
|---|---|
| Title of host publication | xPharm: The Comprehensive Pharmacology Reference |
| Publisher | Elsevier Inc. |
| Pages | 1-5 |
| Number of pages | 5 |
| ISBN (Print) | 9780080552323 |
| DOIs | |
| State | Published - 2011 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
Myasthenia gravis. / Kincaid, Anthony.
xPharm: The Comprehensive Pharmacology Reference. Elsevier Inc., 2011. p. 1-5.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Myasthenia gravis
AU - Kincaid, Anthony
PY - 2011
Y1 - 2011
N2 - Myasthenia gravis is a disorder of neuromuscular transmission that results in skeletal muscle weakness. The affected individual produces antibodies that are directed against their own nicotinic acetylcholine receptors. The circulating antibodies interfere with binding of acetylcholine to the ....
AB - Myasthenia gravis is a disorder of neuromuscular transmission that results in skeletal muscle weakness. The affected individual produces antibodies that are directed against their own nicotinic acetylcholine receptors. The circulating antibodies interfere with binding of acetylcholine to the ....
UR - http://www.scopus.com/inward/record.url?scp=84884059540&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84884059540&partnerID=8YFLogxK
U2 - 10.1016/B978-008055232-3.60686-5
DO - 10.1016/B978-008055232-3.60686-5
M3 - Chapter
AN - SCOPUS:84884059540
SN - 9780080552323
SP - 1
EP - 5
BT - xPharm: The Comprehensive Pharmacology Reference
PB - Elsevier Inc.
ER -